BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 31270272)

  • 1. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells.
    Mestermann K; Giavridis T; Weber J; Rydzek J; Frenz S; Nerreter T; Mades A; Sadelain M; Einsele H; Hudecek M
    Sci Transl Med; 2019 Jul; 11(499):. PubMed ID: 31270272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia.
    Harr MW; Caimi PF; McColl KS; Zhong F; Patel SN; Barr PM; Distelhorst CW
    Cell Death Differ; 2010 Sep; 17(9):1381-91. PubMed ID: 20300113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies.
    Leclercq G; Haegel H; Schneider A; Giusti AM; Marrer-Berger E; Boetsch C; Walz AC; Pulko V; Sam J; Challier J; Ferlini C; Odermatt A; Umaña P; Bacac M; Klein C
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function.
    Salter AI; Ivey RG; Kennedy JJ; Voillet V; Rajan A; Alderman EJ; Voytovich UJ; Lin C; Sommermeyer D; Liu L; Whiteaker JR; Gottardo R; Paulovich AG; Riddell SR
    Sci Signal; 2018 Aug; 11(544):. PubMed ID: 30131370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation.
    Schade AE; Schieven GL; Townsend R; Jankowska AM; Susulic V; Zhang R; Szpurka H; Maciejewski JP
    Blood; 2008 Feb; 111(3):1366-77. PubMed ID: 17962511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. THEMIS-SHP1 Recruitment by 4-1BB Tunes LCK-Mediated Priming of Chimeric Antigen Receptor-Redirected T Cells.
    Sun C; Shou P; Du H; Hirabayashi K; Chen Y; Herring LE; Ahn S; Xu Y; Suzuki K; Li G; Tsahouridis O; Su L; Savoldo B; Dotti G
    Cancer Cell; 2020 Feb; 37(2):216-225.e6. PubMed ID: 32004441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion.
    Zhang H; Hu Y; Shao M; Teng X; Jiang P; Wang X; Wang H; Cui J; Yu J; Liang Z; Ding L; Han Y; Wei J; Xu Y; Li X; Shan W; Shi J; Luo Y; Qian P; Huang H
    J Hematol Oncol; 2021 Jul; 14(1):113. PubMed ID: 34289897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic control of CAR-T cell function using dasatinib.
    Weber EW; Lynn RC; Sotillo E; Lattin J; Xu P; Mackall CL
    Blood Adv; 2019 Mar; 3(5):711-717. PubMed ID: 30814055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic targeting of LCK tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia.
    Laukkanen S; Veloso A; Yan C; Oksa L; Alpert EJ; Do D; Hyvärinen N; McCarthy K; Adhikari A; Yang Q; Iyer S; Garcia SP; Pello A; Ruokoranta T; Moisio S; Adhikari S; Yoder JA; Gallagher K; Whelton L; Allen JR; Jin AH; Loontiens S; Heinäniemi M; Kelliher M; Heckman CA; Lohi O; Langenau DM
    Blood; 2022 Oct; 140(17):1891-1906. PubMed ID: 35544598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential Src family kinase activity requirements for CD3 zeta phosphorylation/ZAP70 recruitment and CD3 epsilon phosphorylation.
    Lysechko TL; Ostergaard HL
    J Immunol; 2005 Jun; 174(12):7807-14. PubMed ID: 15944285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD28 costimulation Impairs the efficacy of a redirected t-cell antitumor attack in the presence of regulatory t cells which can be overcome by preventing Lck activation.
    Kofler DM; Chmielewski M; Rappl G; Hombach A; Riet T; Schmidt A; Hombach AA; Wendtner CM; Abken H
    Mol Ther; 2011 Apr; 19(4):760-7. PubMed ID: 21326215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The tyrosine kinase inhibitor dasatinib reduces the growth of intracellular Mycobacterium tuberculosis despite impairing T-cell function.
    Wehrstedt S; Kubis J; Zimmermann A; Bruns H; Mayer D; Grieshober M; Stenger S
    Eur J Immunol; 2018 Nov; 48(11):1892-1903. PubMed ID: 30242834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of p56(lck) tyrosine kinase by isothiazolones.
    Trevillyan JM; Chiou XG; Ballaron SJ; Tang QM; Buko A; Sheets MP; Smith ML; Putman CB; Wiedeman P; Tu N; Madar D; Smith HT; Gubbins EJ; Warrior UP; Chen YW; Mollison KW; Faltynek CR; Djurić SW
    Arch Biochem Biophys; 1999 Apr; 364(1):19-29. PubMed ID: 10087161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro.
    Blake S; Hughes TP; Mayrhofer G; Lyons AB
    Clin Immunol; 2008 Jun; 127(3):330-9. PubMed ID: 18395492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
    Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
    Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Stüber T; Monjezi R; Wallstabe L; Kühnemundt J; Nietzer SL; Dandekar G; Wöckel A; Einsele H; Wischhusen J; Hudecek M
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-linking of 4-1BB activates TCR-signaling pathways in CD8+ T lymphocytes.
    Nam KO; Kang H; Shin SM; Cho KH; Kwon B; Kwon BS; Kim SJ; Lee HW
    J Immunol; 2005 Feb; 174(4):1898-905. PubMed ID: 15699116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profound inhibition of antigen-specific T-cell effector functions by dasatinib.
    Weichsel R; Dix C; Wooldridge L; Clement M; Fenton-May A; Sewell AK; Zezula J; Greiner E; Gostick E; Price DA; Einsele H; Seggewiss R
    Clin Cancer Res; 2008 Apr; 14(8):2484-91. PubMed ID: 18413841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.
    Walker AJ; Majzner RG; Zhang L; Wanhainen K; Long AH; Nguyen SM; Lopomo P; Vigny M; Fry TJ; Orentas RJ; Mackall CL
    Mol Ther; 2017 Sep; 25(9):2189-2201. PubMed ID: 28676342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crk adaptor proteins regulate CD3ζ chain phosphorylation and TCR/CD3 down-modulation in activated T cells.
    Dong G; Kalifa R; Nath PR; Babichev Y; Gelkop S; Isakov N
    Cell Signal; 2017 Aug; 36():117-126. PubMed ID: 28465009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.